XBIO - Xenetic
- Creatore Discussione davicerr
- Data di inizio
Massimiliano77
Nuovo Utente
- Registrato
- 22/1/19
- Messaggi
- 20
- Punti reazioni
- 0
Ha fatto doppio minimo... vediamo cosa combina...si entra nel vivo...sperem!!!
theantares
Nuovo Utente
- Registrato
- 23/10/20
- Messaggi
- 1.330
- Punti reazioni
- 44
Triplo minimo, considerando marzo 2020
visal
In cul@ al nasdaq
- Registrato
- 20/6/01
- Messaggi
- 23.743
- Punti reazioni
- 290
Questo titolo è di una vergogna assoluta.
No news
No spike
No speculazione
Niente di niente da oltre 1 anno
Ma di quale carburante ha bisogno per farla volare???
fred perry
Uschione
- Registrato
- 12/7/05
- Messaggi
- 7.008
- Punti reazioni
- 202
deve finire la guerra.
secondo te, a Mosca ( in questo periodo storico) daranno mai il via libera ad una azienda Yankee ???
Allora ne abbiamo da aspettare…
beppofinanza
Nuovo Utente
- Registrato
- 7/1/21
- Messaggi
- 616
- Punti reazioni
- 15
Vero!!!
beppofinanza
Nuovo Utente
- Registrato
- 7/1/21
- Messaggi
- 616
- Punti reazioni
- 15
Se novembre inizia così ragazzi .. qui è dura… se non tragica
kada1992
Nuovo Utente
- Registrato
- 12/7/15
- Messaggi
- 1.947
- Punti reazioni
- 102
Si ma il motivo? Non ho trovato nulla
mastrodaniel
Nuovo Utente
- Registrato
- 21/9/05
- Messaggi
- 5.840
- Punti reazioni
- 176
Fa veramente penare....ma oramai aspetto e spero
mastrodaniel
Nuovo Utente
- Registrato
- 21/9/05
- Messaggi
- 5.840
- Punti reazioni
- 176
Uscito il 10q direi non male cash quasi 14 milioni royalty in aumento a 414000 ...market cap 6 milioni
Management evaluates whether there are conditions or events, considered in the aggregate that raise substantial doubt about the Company?s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. These factors raise substantial doubt about its ability to continue as a going concern. The Company believes that it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. The Company believes that its existing resources will be adequate to fund the Company?s operations into the first quarter of 2024. However, the Company anticipates it may need additional capital in the long-term to pursue its business initiatives. The terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in its clinical development programs, its ability to identify and enter into licensing or other strategic arrangements, its continued listing on the Nasdaq Stock Market (?Nasdaq?), and factors related to financial, economic, geo-political, industry and market conditions, many of which are beyond its control. The capital markets for the biotech industry can be highly volatile, which make the terms, timing and extent of any future financing uncertain. On June 3, 2022, the Company received a written notification (the ?Notice?) from the Listing Qualifications Department of Nasdaq notifying the Company that the closing bid price for its common stock had been below $1.00 for 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the ?Bid Price Requirement?). The Notice has no immediate effect on the listing of the Company?s common stock on the Nasdaq Capital Market. Under the Nasdaq Listing Rules, the Company has a period of 180 calendar days from the date of the Notice to regain compliance with the Bid Price Requirement. Accordingly, the Company has until November 30, 2022 to regain compliance with the Bid Price Requirement and may be eligible for an additional 180 calendar day compliance period if certain other criteria are met.
https://fintel.io/doc/sec-xenetic-biosciences-inc-1534525-10q-2022-november-09-19305-3107
https://fintel.io/doc/sec-xenetic-biosciences-inc-1534525-10q-2022-november-09-19305-3107
beppofinanza
Nuovo Utente
- Registrato
- 7/1/21
- Messaggi
- 616
- Punti reazioni
- 15
almeno la società è messa bene, manca solo la quotazione..
https://finance.yahoo.com/news/xenetic-biosciences-inc-reports-third-120500964.html
Per lavorare lavorano e mi sembra anche bene:
Systemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinoma.
Advancing toward planned first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy.
In August 2022, entered into a research and development collaboration agreement with VolitionRX Limited to develop NETs targeted, adoptive cell therapies potentially targeting multiple types of solid cancers.
In June 2022, entered into a manufacturing agreement with Catalent Pharma Solutions LLC, which will include cGMP manufacturing of Phase 1 clinical supply.
Royalty payments of approximately $0.4 million were received in the three months ended September 30, 2022, representing an approximate 18.6% increase over the same period in 2021 as Takeda's sublicensee continued its worldwide launch of the product.
The Company ended the quarter with approximately $13.8 million of cash.
Per lavorare lavorano e mi sembra anche bene:
Systemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinoma.
Advancing toward planned first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy.
In August 2022, entered into a research and development collaboration agreement with VolitionRX Limited to develop NETs targeted, adoptive cell therapies potentially targeting multiple types of solid cancers.
In June 2022, entered into a manufacturing agreement with Catalent Pharma Solutions LLC, which will include cGMP manufacturing of Phase 1 clinical supply.
Royalty payments of approximately $0.4 million were received in the three months ended September 30, 2022, representing an approximate 18.6% increase over the same period in 2021 as Takeda's sublicensee continued its worldwide launch of the product.
The Company ended the quarter with approximately $13.8 million of cash.
temerari....
H.C. Wainwright Keeps Their Buy Rating on Xenetic Biosciences (XBIO)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Xenetic Biosciences (XBIO – Research Report) today and set a price target of $4.00. The company’s shares closed yesterday at $0.39.
According to TipRanks, Pantginis is an analyst with an average return of -19.7% and a 26.95% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Decibel Therapeutics, and Biomea Fusion.
Currently, the analyst consensus on Xenetic Biosciences is a Moderate Buy with an average price target of $4.00.
H.C. Wainwright Keeps Their Buy Rating on Xenetic Biosciences (XBIO)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Xenetic Biosciences (XBIO – Research Report) today and set a price target of $4.00. The company’s shares closed yesterday at $0.39.
According to TipRanks, Pantginis is an analyst with an average return of -19.7% and a 26.95% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Decibel Therapeutics, and Biomea Fusion.
Currently, the analyst consensus on Xenetic Biosciences is a Moderate Buy with an average price target of $4.00.